Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
For semaglutide, the earliest realistic timeline for generic injectable entry: 2029: Generic manufacturers begin bioequivalence studies (2 years before the 2031 method-of-use patent expiration) 2030: ANDA submissions filed 2031-2032: FDA approvals granted, market entry Generic oral semaglutide could follow a faster timeline because Teva's Paragraph IV strategy (using a different absorption enhancer) avoids the SNAC patent entirely: 2026: Teva completes bioequivalence studies (already done as of April 2026) 2026: ANDA submission 2027: FDA approval, market entry The gap between patent expiration and market entry is why patients should not expect immediate cost relief when patents expire
This formula differs from that on Wall Street, which often promotes short-term profits
5 Accessibility remains a key consideration
GLP-1 medications are especially valuable during menopause because they help manage the appetite changes that many women experience during this transition
US$ 20.92
US$ 20.64
US$ 26.59
US$ 22.41
US$ 21.14
US$ 23.81
